COX Share Price

Open 7.52 Change Price %
High 7.52 1 Day -0.07 -0.93
Low 7.35 1 Week -0.11 -1.45
Close 7.46 1 Month 0.22 3.04
Volume 88234 1 Year 5.89 375.16
52 Week High 13.68
52 Week Low 5.80
COX Important Levels
Resistance 2 7.62
Resistance 1 7.55
Pivot 7.44
Support 1 7.37
Support 2 7.30
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
ALEUP 0.28 7.69%
BRS 12.00 0.00%
More..
EPA France Top Gainers Stocks
ALALO 0.03 50.00%
LTAN 2.79 32.86%
ALADO 0.05 25.00%
ALMAS 0.85 23.19%
MLDEX 0.37 19.35%
AB 12.24 17.24%
AB 12.24 17.24%
APAM 33.78 15.72%
APAM 33.78 15.72%
EOS 1.06 15.22%
More..
EPA France Top Losers Stocks
MLDYN 3.63 -18.79%
MLGEO 0.30 -16.67%
AVT 0.05 -16.67%
AVT 0.05 -16.67%
AVT 0.05 -16.67%
AVT 0.05 -16.67%
ALDV 0.08 -11.11%
FIPP 0.14 -6.67%
FIPP 0.14 -6.67%
NEO 26.85 -5.36%
More..

Nicox (EPA: COX)

COX Technical Analysis 5
As on 2nd Dec 2016 COX Share Price closed @ 7.46 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 8.93 & Strong Sell for SHORT-TERM with Stoploss of 8.01 we also expect STOCK to react on Following IMPORTANT LEVELS.
COX Target for December
1st Target up-side 8.16
2nd Target up-side 8.56
3rd Target up-side 8.97
1st Target down-side 7
2nd Target down-side 6.6
3rd Target down-side 6.19
COX Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.nicox.com
COX Address
COX
Drakkar 2 - B
2405 route des Dolines
Sophia Antipolis, 06906
France
Phone: 33 4 97 24 53 00
Fax: 33 4 97 24 53 99
Interactive Technical Analysis Chart Nicox ( COX EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Nicox
COX Business Profile
NicOx S.A. develops a portfolio of therapies and diagnostic tools to enhance sight in the United States, Europe, and internationally. It provides AdenoPlus a diagnostic test that offers eyecare professionals to diagnose and manage patients with an acute red eye. The company’s pipeline product, Latanoprostene bunod, is in Phase III clinical trials for the treatment of glaucoma and ocular hypertension. In addition, it is engaged in the research and development of nitric oxide steroids for the treatment of back and front of the eye disease; and NO-donors for eye disorder applications. Further, the company develops Naproxcinod, an anti-inflammatory candidate that is in regulatory review with the US Food and Drug Administration for the treatment of signs and symptoms of osteoarthritis; nitric oxide for cardiovascular indications; and NCX 1047, a dermatology anti-inflammatory drug-candidate, which is in preclinical stage of development. NicOx S.A. has collaboration with Bausch + Lomb, Merck, and Grupo Ferrer Internacional S.A. The company was founded in 1996 and is headquartered in Sophia Antipolis, France.